EEF2 antibody
Principal name
EEF2 antibody
Alternative names for EEF2 antibody
EF-2, EF2, Elongation factor 2
Ncbi ID
Available reactivities
Available hosts
Available applications
Immunocytochemistry/Immunofluorescence (ICC/IF), Western blot / Immunoblot (WB), Paraffin Sections (P), Enzyme Immunoassay (E), Frozen Sections (C)
Background of EEF2 antibody
Eukaryotic elongation factor 2 (eEF2) catalyzes the translocation of peptidyl-tR from the A site to the P site on the ribosome. It has been shown that phosphorylation of eEF2 at threonine 56 by eEF2 kise inhibits its activity. eEF2 kise is normally dependent on Ca2+ ions and calmodulin. eEF2 kise can also be activated by PKA in response to elevated cAMP levels, which are generally increased in stress- or starvation-related conditions. A variety of treatments known to raise intracellular Ca2+ or cAMP levels have been shown to result in increased phosphorylation of eEF2, and thus to inhibit peptide-chain elongation. The ictive phosphorylated eEF2 can be converted to its active nonphosphorylated form by a protein phosphatase, most likely a form of protein phosphatase-2A (PP-2A). Insulin, which activates protein synthesis in a wide range of cell types, induces rapid dephosphorylation of eEF2 through mTOR sigling and may involve modulation of the activity of the PP-2A or the eEF2 kise or both.
General readings
1. Collodoro M et al. Identification and quantification of concentration-dependent biomarkers in MCF-7/BOS cells exposed to 17ß-estradiol by 2-D DIGE and label-free proteomics. J Proteomics 75:4555-69 (2012). WB ; Human .
Immunohistochemistry (IHC) analyzes of eEF2 antibody (Cat.-No.: AP06094PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of eEF2 antibody (Cat.-No: AP06094PU-N) at 1/500 dilution
Lane1:HepG2 cell lysate
Lane2:Mouse kidney tissue lysate
Lane3:Rat kidney tissue lysate
Lane1:HepG2 cell lysate
Lane2:Mouse kidney tissue lysate
Lane3:Rat kidney tissue lysate
Human Small intestine; Small intestine; EEF2 antibody - N-terminal region (ARP58457_P050) in Human Small intestine cells using Immunohistochemistry
Human HeLa; WB Suggested Anti-EEF2 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: Hela cell lysate; EEF2 antibody - N-terminal region (ARP58457_P050) in Human HeLa cells using Western Blot
Immunohistochemical analysis of paraffin-embedded liver cancer tissues (left) and kidney cancer tissues (right) using EEF2 antibody Cat.-No AM06603SU-N with DAB staining.
Immunohistochemical analysis of paraffin-embedded prostate cancer tissues (left) and tonsil tissues (right) using antibody Cat.-No AM06603SU-N with DAB staining.
Immunofluorescence analysis of 3T3-L1 cells using EEF2 antibody Cat.-No AM06603SU-N (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Western blot analysis using EEF2 antibody Cat.-No AM06603SU-N against HepG2 (Lane 1), Hela (Lane 2), HEK293 (Lane 3) and A431 (Lane 4) cell lysate.
Immunohistochemical analysis of EEF2 staining in human lung cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
Immunofluorescent analysis of EEF2 staining in A431 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Western blot analysis of EEF2 expression in A431 (A); MCF7 (B); mouse kidney (C); rat kidney (D) whole cell lysates.
Western blot analysis of extracts of various cell lines , using EEF2 antibody.
Immunohistochemical of paraffin-embedded rat spleen using EEF2 antibody at dilution of 1:100 (200x lens).
WB Suggested Anti-EEF2 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1:312500; Positive Control: Hela cell lysate
Small intestine
Western blot detection of eEF2 in HL-60,Jurkat,SHSY-5Y,U20S and Hela cell lysates using eEF2 mouse mAb (1:5000 diluted).Predicted band size:95KDa.Observed band size: 95KDa.Exposure time:15s.
Immunocytochemistry staining of HeLa cells fixed with -20? Methanol and using anti-eEF2 mouse mAb (dilution 1:200).
Gel: 6%SDS-PAGE, Lysate: 40 ug, Lane 1-6: LoVo cells, HepG2 cells, NIH/3T3 cells, MCF7 cells, 293T cells, Hela cells, Primary antibody: (EEF2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using (EEF2 Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using (EEF2 Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)
- Quick-Filters:
- Highly Validated (1)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AM06603SU-N | EEF2 antibody |
||||||
 |
Mouse | IgG1 | 5B6 | Ascites | Hu | E, ICC/IF, P, WB |
0.1 ml /
€410.00
|
| OriGene Technologies GmbH | |||||||
 +4 additional images |
Highly validated antibody! |
||||||
| TA327253 | EEF2 antibody |
||||||
| EEF2 Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt |
0.1 mg /
€335.00
|
||
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA346936 | EEF2 antibody |
||||||
| Mouse Monoclonal eEF2 Antibody | |||||||
 |
Mouse | IgG2b | 4B3-G7-H5 | Purified | ICC/IF, WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA349920 | EEF2 antibody |
||||||
| Rabbit Polyclonal Anti-EEF2 Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P, WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +2 additional images |
|||||||
| AP06094PU-N | EEF2 antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 mg /
€370.00
|
||
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| AP54914SU-N | EEF2 antibody |
||||||
 |
Rabbit | Serum | Hu | C, E, WB |
0.2 ml /
€430.00
|
||
| OriGene Technologies GmbH | |||||||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP312420 | EEF2 |
||||
| Recombinant protein of human eukaryotic translation elongation factor 2 (EEF2) | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR210973L2V | Lenti ORF particles, Eef2 (GFP-tagged) - Mouse eukaryotic translation elongation factor 2 (Eef2), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,690.00
|
|
| OriGene Technologies, Inc. | ||
| MR210973L1V | Lenti ORF particles, Eef2 (Myc-DDK-tagged) - Mouse eukaryotic translation elongation factor 2 (Eef2), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,520.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR202878L2V | Lenti ORF particles, Eef2 (GFP-tagged ORF) - Rat eukaryotic translation elongation factor 2 (Eef2), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,690.00
|
|
| OriGene Technologies, Inc. | ||
| RR202878L1V | Lenti ORF particles, Eef2 (Myc-DDK-tagged ORF) - Rat eukaryotic translation elongation factor 2 (Eef2), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,520.00
|
|
| OriGene Technologies, Inc. | ||